Ulcerative Colitis Drug Market Double Next Decade., Sales of drugs to treat ulcerative colitis in seven major markets are set to double over the next decade, reaching $3.7 billion by 2021, according new research.

This fast growth will be primarily driven by two premium-priced tumour necrosis factor-alpha (TNF-alpha) inhibitors – /Eisai’s Humira (adalimumab) and Janssen/Merck/Mitsubishi Tanabe’s Simponi (golimumab) – plus two novel therapies – Takeda’s (CAM) inhibitor and ’s oral Janus-activated kinase inhibitor tofacitinib – says the report, from Decision Resources.

The market will also be boosted over this period by the expanding number of diagnosed prevalent cases of ulcerative colitis in the seven markets – , , , , , and US, it adds.

Ulcerative colitis drug market “to double over next decade”

Sales of drugs to treat ulcerative colitis in seven major markets are set to double over the next decade, reaching $3.7 billion by 2021, according new research. This fast growth will be primarily driven by two premium-priced tumour necrosis factor

Leave a Reply